Clinical trialPhase 1 / Phase 2Withdrawn
HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Cancer
HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Cancer: Clinical Trial
- Outcome
- Stopped early
- Phase
- Phase 1 / Phase 2
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- May 2015
- Planned end
- June 2020
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Number of participants with Adverse events
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 12 September 2019
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction Angiography(DSA)for pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction Angiography(DSA)for pancreatic cancer.